Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a novel fiber shaft structural motif and overexpression of key transcripts elucidated in human adenovirus D 10.

PLoS pathogens·2026
Same author

Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.

Molecular therapy. Oncology·2026
Same author

GP73: the key to unlocking immunotherapies efficacy in solid tumors?

Journal for immunotherapy of cancer·2025
Same author

Netrin-1 stimulated axon growth requires the polyglutamylase TTLL1.

Frontiers in neuroscience·2024
Same author

The αvβ6 integrin specific virotherapy, Ad5<sub>NULL</sub>-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancreatic ductal adenocarcinoma.

British journal of cancer·2024
Same author

A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications.

Molecular therapy. Methods & clinical development·2024

Related Experiment Video

Updated: Jul 29, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Engineering Adenoviral Vectors with Improved GBM Selectivity.

Emily A Bates1, Charlotte Lovatt1, Alice R Plein1

  • 1Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.

Viruses
|May 27, 2023
PubMed
Summary
This summary is machine-generated.

Oncolytic adenovirus therapies for glioblastoma (GBM) show promise. Researchers engineered adenovirus to target GBM cells specifically, overcoming limitations of standard adenovirus 5 (HAdV-C5) and enhancing treatment efficacy.

Keywords:
brain tumouroncolytic virusreceptortherapy

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.7K
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

8.3K

Related Experiment Videos

Last Updated: Jul 29, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.7K
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

8.3K

Area of Science:

  • Oncolytic virotherapy
  • Cancer biology
  • Gene therapy

Background:

  • Glioblastoma (GBM) is an aggressive brain cancer with poor prognosis.
  • Oncolytic adenoviruses offer a potential therapeutic strategy for GBM.
  • Human adenovirus 5 (HAdV-C5) use is limited by pre-existing immunity and off-target effects.

Purpose of the Study:

  • To investigate alternative adenoviral tropisms for improved GBM targeting.
  • To develop strategies for enhancing GBM-specific transgene expression.

Main Methods:

  • Adenovirus platform pseudotyped with fiber knob proteins from alternative serotypes.
  • Analysis of adenoviral receptor expression (CAR, CD46, DSG2) in GBM and healthy brain tissue.
  • Utilized tumor-specific promoters (hTERT, survivin) to drive reporter gene expression.

Main Results:

  • Adenoviral pseudotypes effectively transduced GBM cells via CAR, CD46, and DSG2.
  • These receptors are also present on healthy brain cells, indicating potential off-target effects.
  • Tumor-specific promoters (hTERT, survivin) demonstrated selective reporter gene expression in GBM cell lines.

Conclusions:

  • Pseudotyping adenoviruses can enhance GBM cell transduction.
  • Combining pseudotyping with tumor-specific promoters offers a strategy to improve GBM therapy specificity.
  • This approach may lead to more efficacious and targeted oncolytic virotherapies for glioblastoma.